ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0698

Cohort Study of Cigarette Smoking and the Risk of Developing Polymyalgia Rheumatica Among Women

Jae Hee Kang1, Susan Malspeis2, Nicole Yang2 and Karen Costenbader2, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA

Meeting: ACR Convergence 2022

Keywords: Epidemiology, Polymyalgia Rheumatica (PMR), risk factors, Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease among older White women, but little is known of its etiology and there are few established risk factors. Cigarette smoking is a common risk factor for several rheumatic diseases; however, its relationship with PMR has been studied in only two past studies with inconsistent results. We aimed to investigate the association between cigarette smoking and PMR risk among women.

Methods: We used data from the Nurses’ Health Study (NHS) and NHSII, ongoing longitudinal cohorts of US female registered nurses (NHS, 1976-2018, aged 30-55 at enrollment in 1976; NHSII, 1989-2019, aged 25-42 at enrollment in 1989). Participants provided updated information on lifestyle such as cigarette smoking and health conditions on biennial questionnaires. In the latest 2021 questionnaire, we asked participants to specifically self-report a history of a physician-diagnosis of PMR and date of diagnosis. Eligible participants were women aged 50 years or older and were free of PMR at enrollment. The data from the two cohorts were combined due to lack of heterogeneity of the cohort-specific results. Cox proportional hazards regression models, stratified by cohort and 2-year risk period with age as the time scale, were used to estimate multivariable-adjusted hazard ratios (HRs) with 95% confidence intervals (95%CIs) for incident PMR.

Results: We studied 69,109 NHS and NHSII women during a total follow-up of 1,763,239 person-years (Table 1). Among them, 574 PMR cases were identified. Mean age at diagnosis was 62, SD 8.5 overall; 68.7, SD 7.5 years in NHS; and 59.4, SD 7.3 years in NHSII. While a history of any smoking (HR 1.13, 95%CI 0.94, 1.35) or current smoking (HR 1.20, 95%CI 0.82, 1.78) were not associated with risk, 20+ pack-years of smoking was positively associated with higher incident PMR, with a significant linear trend (p linear trend 0.003; Table 2: Figure 1). HRs were 0.99 (95%CI 0.78, 1.26) for 1-9 pack-years; 1.03 (95%CI 0.78, 1.35) for 10-19 pack-years and 1.46 (95%CI 1.14, 1.88) for 20 or more pack-years. Every 10 pack-years of smoking was associated with a 9% (95%CI 2%,16%) increase in PMR risk. To evaluate whether smoking during earlier periods was associated with PMR risk, we conducted lagged analyses evaluating pack-year status as of 4 years or 8 years before the risk period or status as of baseline and results were robust (Table 2).

Conclusion: Twenty pack-years or more of cigarette smoking was associated with a modestly higher risk of incident PMR among women in these large prospectively followed cohorts of women. This is an important public health finding and other risk factors for PMR should also be investigated.

Supporting image 1

Supporting image 2

Supporting image 3

Figure 1. Spline Analysis showing multivariable hazard ratio (with 95%CIs) for pack-years of cigarette smoking and risk of PMR among women in the NHS cohorts


Disclosures: J. Kang, None; S. Malspeis, None; N. Yang, None; K. Costenbader, Eli Lilly, Janssen, Amgen, AstraZeneca Pharmaceuticals LP, GlaxoSmithKline(GSK), Gilead, Exagen, Neutrolis, Cel-Sci, Alkermes.

To cite this abstract in AMA style:

Kang J, Malspeis S, Yang N, Costenbader K. Cohort Study of Cigarette Smoking and the Risk of Developing Polymyalgia Rheumatica Among Women [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/cohort-study-of-cigarette-smoking-and-the-risk-of-developing-polymyalgia-rheumatica-among-women/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cohort-study-of-cigarette-smoking-and-the-risk-of-developing-polymyalgia-rheumatica-among-women/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology